IN8BIO INC (INAB:NASDAQ)
$0.9809 -0.0691 (-6.581%)
Analysed IN8BIO INC (INAB:NASDAQ) News Sources
IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026
01-06-2026
yahoo.com
IN8bio to Present at H.C. Wainwright 28th Annual Global Investment Conference
10-09-2026
yahoo.com
IN8bio to Showcase Next-Generation T Cell Engager Platform and New Clinical Data at Upcoming R&D Day and Medical Conferences
06-05-2026
yahoo.com
IN8bio Presents New Translational Data Demonstrating DeltEx DRI Reshapes the Immune Landscape in Glioblastoma
14-05-2026
yahoo.com
IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights
07-05-2026
yahoo.com
IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma
09-07-2026
yahoo.com
IN8bio Reports Second Quarter 2026 Financial Results and Recent Business Highlights
06-08-2026
yahoo.com
IN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development
09-09-2026
yahoo.com
IN8bio to Present at Sidoti Small-Cap Virtual Conference
22-09-2026
yahoo.com
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
06-10-2026
yahoo.com
What is the current price of IN8BIO INC (INAB:NASDAQ)?
The current price of IN8BIO INC (INAB:NASDAQ) is $0.9809.
IN8BIO INC (INAB:NASDAQ) absolute price change since previous trading day?
The absolute price change of IN8BIO INC (INAB:NASDAQ) since the previous trading day is $-0.0691.
IN8BIO INC (INAB:NASDAQ) percentage price change since previous trading day?
The percentage price change of IN8BIO INC (INAB:NASDAQ) since the previous trading day is -6.581%.
What is the most recent average sentiment score for IN8BIO INC (INAB:NASDAQ)?
The most recent average sentiment score for IN8BIO INC (INAB:NASDAQ) is 76 out of 100.
What is the most recent average sentiment for IN8BIO INC (INAB:NASDAQ)?
The most recent sentiment for IN8BIO INC (INAB:NASDAQ) is .
SEC-8K** Filing Available For IN8BIO INC (INAB:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.